Brian Gerardo
Chief Operating Officer and Chief Financial Officer
Replay available
Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call
Gossamer Bio, Inc. (NASDAQ: GOSS) Q1 2026 earnings conference call, held 2026-05-18. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Fahim Hasning
Chief Executive Officer
Karen Peterson
Head of Regulatory Affairs
Dr. Rob Resigno
CT-FRI Substudy Lead
Bob Smith
Chief Commercial Officer
Dr. Jean-Marie Bruy
FRI Platform Expert
Vamil Devant
Analyst, Guggenheim Securities
Unknown Participant
Analyst
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Gossamer Bio, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.418 Thank you for standing by. My name is Tina, and I will be your conference operator today. 00:00:04.418 -- 00:00:09.466 At this time, I would like to welcome everyone to the Gossamer Dio 00:00:09.466 -- 00:00:11.188 Q1 2026 00:00:11.188 -- 00:00:16.837 earnings call. All lines have been placed on mute to prevent any background noise. 00:00:16.837 -- 00:00:20.443 After the speaker's remarks, there will be a question and answer session. 00:00:20.443 -- 00:00:25.431 To ask a question, simply press star 1 on your telephone keypad. 00:00:25.431 -- 00:00:28.499 To withdraw your question, press star 1 again. 00:00:28.499 -- 00:00:33.667 It is now my pleasure to turn the call over to Brian Gerardo, Chief Operating Officer 00:00:33.667 -- 00:00:38.011 and Chief Financial Officer. Please go ahead. 00:00:38.755 -- 00:00:40.557 Good morning, and thank you for joining us. 00:00:40.557 -- 00:00:44.484 Before we begin, I'd like to remind listeners that today's discussion includes forward-looking 00:00:44.484 -- 00:00:49.311 statements, including statements regarding our regulatory plans, potential NDA submission, 00:00:49.311 -- 00:00:53.858 and approval timing, commercialization, expectations, cash runway, capital structure, 00:00:53.858 -- 00:00:57.676 and the potential therapeutic benefit in future developments of Sarah Lutonit. 00:00:57.676 -- 00:01:01.641 These statements are subject to risks and uncertainties that could cause actual results 00:01:01.641 -- 00:01:06.627 to differ materially. Please refer to our SEC filings in today's press release for discussions 00:01:06.627 -- 00:01:11.133 of these risks. We undertake no obligation to update these forward-looking statements 00:01:11.133 -- 00:01:14.194 except as required by law. 00:01:14.33...